STOCK TITAN

Intellia Therapeutics Inc - NTLA STOCK NEWS

Welcome to our dedicated news page for Intellia Therapeutics (Ticker: NTLA), a resource for investors and traders seeking the latest updates and insights on Intellia Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Intellia Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Intellia Therapeutics's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.33%
Tags
management
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.93%
Tags
earnings
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.12%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-19.22%
Tags
clinical trial
-
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.26%
Tags
earnings
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.92%
Tags
none
Intellia Therapeutics Inc

Nasdaq:NTLA

NTLA Rankings

NTLA Stock Data

2.60B
94.53M
1.33%
87.34%
13.13%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Cambridge

About NTLA

intellia therapeutic’s core mission is to develop curative medicines, utilizing the promise of the crispr/cas9 gene editing technology. the development of crispr/cas9 gene editing technology opens a new frontier in biomedical research and clinical intervention. adapted from a natural cellular process, crispr/cas9 permits the editing of any gene in any organism with unprecedented simplicity and flexibility. the incredible potential of this technology for treating human genetic disease inspired a group of life science veterans to create intellia therapeutics. intellia was founded in 2014 by caribou biosciences and atlas venture, along with a consortium of scientists who have helped define the space. intellia therapeutics holds exclusive access to a broad intellectual property portfolio covering the application of crispr/cas9 technology for human therapeutic use. intellia has built an experienced team of individuals to meet the challenges of bringing crispr/cas9 therapeutics to the